Baxter International, Inc. Builds On Global Leadership In Hemophilia A
Published: May 28, 2014
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX) continues to build upon its global leadership position in hemophilia with ADVATE [Antihemophilic Factor (Recombinant)], the first recombinant treatment with no human or animal protein additives for patients with hemophilia A. ADVATE continues to be the most prescribed full-length recombinant FVIII worldwide, with more than 10 years of real-world experience and over 17 billion units distributed.
Help employers find you! Check out all the jobs and post your resume.